Induction of severe systemic lupus erythematosus by TNF blockade and response to anti–IL-6 strategy

Because the disease did not respond to treatment with cyclophosphamide, we finally introduced infliximab to block the TNF pathway. [...]we strongly believe that clinical reasoning should involve consideration of the molecular effects of therapeutic interventions.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2013-04, Vol.131 (4), p.1235-1237.e1
Hauptverfasser:	Adler, Sabine, MD, Kolev, Mirjam, MD, Varisco, Pierre-Alain, MD, Tham, Manuela, von Gunten, Michael, MD, Tappeiner, Christoph, MD, Villiger, Peter M., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Allergy and Immunology Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antibodies, Antinuclear - blood Antibodies, Antinuclear - immunology Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Autoimmune diseases Biological and medical sciences Bone marrow Drug therapy Endocarditis - drug therapy Endocarditis - etiology Endocarditis - immunology Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunopathology Inflammation - immunology Inflammation - pathology Infliximab Interleukin-6 - antagonists & inhibitors Interleukin-6 - immunology Lupus Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - etiology Lupus Erythematosus, Systemic - immunology Male Medical sciences Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Scleritis - drug therapy Scleritis - immunology Scleritis - pathology Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Because the disease did not respond to treatment with cyclophosphamide, we finally introduced infliximab to block the TNF pathway. [...]we strongly believe that clinical reasoning should involve consideration of the molecular effects of therapeutic interventions.
ISSN:	0091-6749 1097-6825
DOI:	10.1016/j.jaci.2012.09.034